A combination of Atomoxetine + Oxybutynin is researched for treating obstructive sleep apnea. Studies indicate that it is highly effective for many people with AHI-reductions of around 50% to 70%.
Since the pathophysiology of obstructive sleep apnea and UARS overlap, this leads to the following question: Could this work for UARS?
What do you think?
A custom brain implant has put a man’s 30-year depression into remission.
It literally targets his unique neural pathways.
A man who endured severe, treatment-resistant depression for over three decades has achieved full remission thanks to a groundbreaking, bespoke brain "pacemaker."
Unlike conventional treatments that use a "one-size-fits-all" approach, this experimental procedure—known as Personalized Adaptive Cortical Electro-stimulation (PACE)—selectively activates specific regions of the patient's brain tailored to his unique neural architecture.
By mapping the individual’s brain networks using functional MRI, researchers at the University of Minnesota were able to identify precise targets for electrode implantation. This personalized mapping allowed the device to trigger feelings of joy and emotional access for the first time in the patient’s adult life, bypassing the limitations of standard therapies.
This innovation addresses a critical gap in mental health care for the millions of people who see no improvement from traditional antidepressants or electroconvulsive therapy (ECT). Damien Fair and the research team highlighted that because every brain is structurally different, generic stimulation often misses the exact regions necessary for individual relief. In this case, the device fine-tuned its electrical pulses based on real-time feedback, leading to the complete disappearance of suicidal thoughts within seven weeks and full remission within nine months. This success marks a shift toward precision medicine in psychiatry, offering a potential lifeline for those with chronic conditions that have long been considered untreatable.